REGENXBIO (RGNX) Financials

$8.68 -0.29 (-3.23%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$8.92 +0.24 (+2.81%)

As of 05/30/2025 07:48 PM Eastern

Annual Income Statements for REGENXBIO

This table shows REGENXBIO's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-227	-263	-280
Consolidated Net Income / (Loss)	-227	-263	-280
Net Income / (Loss) Continuing Operations	-227	-263	-280
Total Pre-Tax Income	-227	-264	-280
Total Operating Income	-233	-268	-263
Total Gross Profit	55	53	58
Total Revenue	83	90	113
Operating Revenue	83	90	113
Total Cost of Revenue	29	37	55
Operating Cost of Revenue	34	37	55
Other Cost of Revenue	-5.00	0.00	0.00
Total Operating Expenses	288	321	321
Selling, General & Admin Expense	77	88	85
Research & Development Expense	209	232	242
Other Operating Expenses / (Income)	0.87	0.40	-6.68
Impairment Charge	2.10	0.00	0.00
Total Other Income / (Expense), net	6.24	4.48	-18
Interest Expense	13	6.86	23
Interest & Investment Income	19	11	5.38
Other Income / (Expense), net	0.17	0.03	0.34
Income Tax Expense	0.00	-0.15	-0.08
Basic Earnings per Share	($4.59)	($6.02)	($6.50)
Weighted Average Basic Shares Outstanding	49.51M	43.73M	43.15M
Diluted Earnings per Share	($4.59)	($6.02)	($6.50)
Weighted Average Diluted Shares Outstanding	49.51M	43.73M	43.15M
Weighted Average Basic & Diluted Shares Outstanding	50.09M	44.43M	43.46M

This table shows REGENXBIO's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-51	-60	-53	-63	-63	-62	-72	-67	-60	-75
Consolidated Net Income / (Loss)	-51	-60	-53	-63	-63	-62	-72	-67	-60	-75
Net Income / (Loss) Continuing Operations	-52	-60	-53	-63	-62	-62	-72	-67	-60	-75
Total Pre-Tax Income	-51	-60	-53	-63	-63	-62	-72	-67	-60	-75
Total Operating Income	-51	-62	-56	-64	-64	-65	-73	-66	-58	-71
Total Gross Profit	20	12	12	11	11	17	11	15	19	13
Total Revenue	21	24	22	16	22	29	20	19	31	27
Operating Revenue	21	24	22	16	22	29	20	19	31	27
Total Cost of Revenue	1.32	12	11	4.28	11	12	9.48	4.11	13	13
Operating Cost of Revenue	6.32	12	11	4.28	11	12	9.48	4.11	13	13
Total Operating Expenses	71	74	68	75	75	81	84	81	76	84
Selling, General & Admin Expense	20	19	19	18	19	23	24	23	21	21
Research & Development Expense	50	54	49	55	56	58	60	59	63	63
Other Operating Expenses / (Income)	0.83	0.04	0.03	-0.03	0.12	0.22	0.03	0.03	-7.38	0.23
Total Other Income / (Expense), net	0.18	2.48	3.05	0.53	0.86	3.09	1.05	-0.52	-2.21	-4.44
Interest Expense	9.42	0.82	0.45	1.97	1.36	1.62	1.12	2.76	4.31	5.95
Interest & Investment Income	9.52	3.28	3.47	2.47	2.37	4.66	2.13	2.17	2.03	1.50
Other Income / (Expense), net	0.08	0.03	0.03	0.04	-0.14	0.06	0.04	0.07	0.08	0.02
Basic Earnings per Share	($0.99)	($1.17)	($1.05)	($1.38)	($1.42)	($1.41)	($1.66)	($1.53)	($1.38)	($1.75)
Weighted Average Basic Shares Outstanding	49.51M	50.80M	50.60M	45.73M	43.73M	43.95M	43.53M	43.45M	43.15M	43.25M
Diluted Earnings per Share	($0.99)	($1.17)	($1.05)	($1.38)	($1.42)	($1.41)	($1.66)	($1.53)	($1.38)	($1.75)
Weighted Average Diluted Shares Outstanding	49.51M	50.80M	50.60M	45.73M	43.73M	43.95M	43.53M	43.45M	43.15M	43.25M
Weighted Average Basic & Diluted Shares Outstanding	50.09M	49.55M	49.42M	49.26M	44.43M	43.99M	43.96M	43.47M	43.46M	43.29M

This table details how cash moves in and out of REGENXBIO's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	23	-62	-248
Net Cash From Operating Activities	-173	-218	-207
Net Cash From Continuing Operating Activities	-173	-218	-207
Net Income / (Loss) Continuing Operations	-227	-263	-280
Consolidated Net Income / (Loss)	-227	-263	-280
Depreciation Expense	16	17	13
Amortization Expense	-4.14	0.69	4.71
Non-Cash Adjustments To Reconcile Net Income	34	37	45
Changes in Operating Assets and Liabilities, net	7.42	-10	10
Net Cash From Investing Activities	103	191	-12
Net Cash From Continuing Investing Activities	103	191	-12
Purchase of Property, Plant & Equipment	-2.44	-9.96	-31
Purchase of Investments	-190	-87	-185
Sale and/or Maturity of Investments	296	287	204
Net Cash From Financing Activities	93	-35	-29
Net Cash From Continuing Financing Activities	93	-35	-29
Issuance of Common Equity	132	6.70	1.74
Other Financing Activities, net	-40	-42	-31
Cash Income Taxes Paid	-0.07	-0.14	12

This table details how cash moves in and out of REGENXBIO's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	0.91	-1.15	-55	78	-19	-16	-1.27	-27	-22	-2.83
Net Cash From Operating Activities	-32	-41	-45	-55	-41	-49	-47	-81	-39	-50
Net Cash From Continuing Operating Activities	-32	-41	-45	-55	-41	-49	-47	-81	-39	-50
Net Income / (Loss) Continuing Operations	-51	-60	-53	-63	-63	-62	-72	-67	-60	-75
Consolidated Net Income / (Loss)	-51	-60	-53	-63	-63	-62	-72	-67	-60	-75
Depreciation Expense	4.02	3.96	4.05	4.18	4.34	4.37	4.44	4.18	4.13	3.55
Amortization Expense	-1.12	-1.32	-1.24	-0.47	-0.24	-0.13	0.38	0.68	0.90	1.13
Non-Cash Adjustments To Reconcile Net Income	4.55	9.91	8.22	12	8.69	8.63	7.87	12	9.61	13
Changes in Operating Assets and Liabilities, net	12	6.49	-3.54	-7.64	9.34	-0.40	12	-31	5.93	6.96
Net Cash From Investing Activities	40	50	-0.27	13	34	39	55	63	27	53
Net Cash From Continuing Investing Activities	40	50	-0.27	13	34	39	55	63	27	53
Purchase of Property, Plant & Equipment	-1.08	-0.33	-0.47	-0.56	-1.13	-1.44	-2.58	-4.82	-5.47	-5.05
Purchase of Investments	-16	-36	-83	-55	-19	-18	-50	0.00	-12	-15
Sale and/or Maturity of Investments	58	87	83	69	54	58	108	68	44	73
Net Cash From Financing Activities	-7.74	-11	-9.45	121	-12	-4.81	-9.16	-9.04	-8.92	-5.42
Net Cash From Continuing Financing Activities	-7.74	-11	-9.45	121	-12	-4.81	-9.16	-9.04	-8.92	-5.42
Other Financing Activities, net	-7.74	-11	-9.20	-11	-12	-11	-9.16	-9.62	-8.92	-6.54

This table presents REGENXBIO's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	466	574	833
Total Current Assets	278	335	416
Cash & Equivalents	58	35	97
Short-Term Investments	177	241	268
Accounts Receivable	20	25	28
Prepaid Expenses	9.07	15	14
Other Current Assets	14	20	9.35
Plant, Property, & Equipment, net	118	132	142
Total Noncurrent Assets	70	107	276
Long-Term Investments	10	39	201
Noncurrent Note & Lease Receivables	0.47	0.70	1.50
Other Noncurrent Operating Assets	58	65	72
Other Noncurrent Nonoperating Assets	2.03	2.03	2.03
Total Liabilities & Shareholders' Equity	466	574	833
Total Liabilities	206	262	317
Total Current Liabilities	103	130	130
Accounts Payable	23	23	27
Accrued Expenses	38	50	47
Current Deferred Revenue	0.12	0.15	1.83
Other Current Liabilities	42	58	55
Total Noncurrent Liabilities	103	132	187
Other Noncurrent Operating Liabilities	103	132	187
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	260	312	516
Total Preferred & Common Equity	260	312	516
Preferred Stock	0.00	0.00	0.00
Total Common Equity	260	312	516
Common Stock	1,193	1,021	973
Retained Earnings	-932	-705	-442
Accumulated Other Comprehensive Income / (Loss)	-0.74	-4.43	-15

This table presents REGENXBIO's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	519	569	629	634	682	748	884
Total Current Assets	313	347	395	366	379	389	437
Cash & Equivalents	57	58	113	53	69	70	119
Short-Term Investments	199	233	226	249	251	262	264
Accounts Receivable	24	23	16	28	21	19	33
Prepaid Expenses	11	10	14	13	15	16	15
Other Current Assets	23	23	27	23	22	23	6.85
Plant, Property, & Equipment, net	121	124	128	136	139	142	141
Total Noncurrent Assets	85	99	106	132	165	217	306
Long-Term Investments	23	37	42	63	95	142	235
Noncurrent Note & Lease Receivables	0.40	0.46	0.52	1.08	1.14	1.30	1.80
Other Noncurrent Operating Assets	60	59	62	66	66	72	68
Other Noncurrent Nonoperating Assets	2.03	2.03	2.03	2.26	2.26	2.03	2.03
Total Liabilities & Shareholders' Equity	519	569	629	634	682	748	884
Total Liabilities	218	221	239	271	277	283	320
Total Current Liabilities	103	98	110	127	118	112	124
Accounts Payable	20	16	31	22	12	23	25
Accrued Expenses	49	42	33	46	51	32	44
Current Deferred Revenue	0.14	0.02	0.01	0.44	0.45	1.31	5.90
Other Current Liabilities	34	39	46	59	55	56	48
Total Noncurrent Liabilities	115	123	128	143	159	170	196
Other Noncurrent Operating Liabilities	115	123	128	143	159	170	196
Total Equity & Noncontrolling Interests	301	348	391	363	406	465	564
Total Preferred & Common Equity	301	348	391	363	406	465	564
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	301	348	391	363	406	465	564
Common Stock	1,183	1,172	1,162	1,013	996	985	964
Retained Earnings	-881	-821	-768	-642	-580	-508	-382
Accumulated Other Comprehensive Income / (Loss)	-0.58	-2.27	-3.23	-7.41	-10	-12	-18

This table displays calculated financial ratios and metrics derived from REGENXBIO's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-7.66%	-19.94%	-76.03%
EBITDA Growth	11.59%	-2.12%	-239.07%
EBIT Growth	13.03%	-2.12%	-263.37%
NOPAT Growth	12.97%	-2.00%	-227.09%
Net Income Growth	13.81%	6.00%	-319.27%
EPS Growth	23.75%	7.38%	-323.37%
Operating Cash Flow Growth	20.73%	-5.26%	-194.80%
Free Cash Flow Firm Growth	22.96%	-6.48%	-356.63%
Invested Capital Growth	388.77%	91.35%	41.39%
Revenue Q/Q Growth	-1.18%	-9.19%	-75.56%
EBITDA Q/Q Growth	4.97%	-3.00%	-286.16%
EBIT Q/Q Growth	5.19%	-2.43%	-328.50%
NOPAT Q/Q Growth	5.10%	-2.34%	-300.39%
Net Income Q/Q Growth	4.90%	-1.13%	-480.68%
EPS Q/Q Growth	8.57%	-0.67%	-477.91%
Operating Cash Flow Q/Q Growth	5.01%	-0.64%	-219.67%
Free Cash Flow Firm Q/Q Growth	8.19%	0.27%	-398.86%
Invested Capital Q/Q Growth	-38.73%	-19.99%	7.57%
Profitability Metrics	-	-	-
Gross Margin	65.72%	58.76%	51.61%
EBITDA Margin	-265.34%	-277.14%	-217.27%
Operating Margin	-280.03%	-297.12%	-233.20%
EBIT Margin	-279.82%	-297.09%	-232.90%
Profit (Net Income) Margin	-272.54%	-291.99%	-248.68%
Tax Burden Percent	100.00%	99.94%	99.97%
Interest Burden Percent	97.40%	98.34%	106.81%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-3,918.02%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-3,895.37%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	3,838.53%	0.00%	0.00%
Return on Equity (ROE)	-79.49%	-63.65%	-43.78%
Cash Return on Invested Capital (CROIC)	-1,415.24%	0.00%	0.00%
Operating Return on Assets (OROA)	-44.84%	-38.10%	-26.97%
Return on Assets (ROA)	-43.68%	-37.45%	-28.79%
Return on Common Equity (ROCE)	-79.49%	-63.65%	-43.78%
Return on Equity Simple (ROE_SIMPLE)	-87.46%	-84.52%	-54.31%
Net Operating Profit after Tax (NOPAT)	-163	-188	-184
NOPAT Margin	-196.02%	-207.98%	-163.24%
Net Nonoperating Expense Percent (NNEP)	-22.65%	-17.16%	-13.58%
Return On Investment Capital (ROIC_SIMPLE)	-62.91%	-60.21%	-35.65%
Cost of Revenue to Revenue	34.28%	41.24%	48.39%
SG&A Expenses to Revenue	91.95%	98.06%	75.65%
R&D to Revenue	250.24%	257.38%	215.09%
Operating Expenses to Revenue	345.75%	355.88%	284.82%
Earnings before Interest and Taxes (EBIT)	-233	-268	-263
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-221	-250	-245
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.48	2.53	1.90
Price to Tangible Book Value (P/TBV)	1.48	2.53	1.90
Price to Revenue (P/Rev)	4.60	8.75	8.71
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	10.83	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.66	5.27	3.70
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.99	-1.07	-1.11
Leverage Ratio	1.82	1.70	1.52
Compound Leverage Factor	1.77	1.67	1.62
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-2.71	-0.87	0.62
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.69	2.57	3.19
Quick Ratio	2.47	2.30	3.01
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-181	-234	-220
Operating Cash Flow to CapEx	-7,106.94%	-2,192.84%	-675.33%
Free Cash Flow to Firm to Interest Expense	-14.26	-34.15	-9.46
Operating Cash Flow to Interest Expense	-13.68	-31.83	-8.92
Operating Cash Flow Less CapEx to Interest Expense	-13.87	-33.28	-10.24
Efficiency Ratios	-	-	-
Asset Turnover	0.16	0.13	0.12
Accounts Receivable Turnover	3.68	3.41	3.73
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.67	0.66	0.83
Accounts Payable Turnover	1.25	1.49	2.83
Days Sales Outstanding (DSO)	99.13	106.93	97.98
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	291.21	245.21	129.15
Cash Conversion Cycle (CCC)	-192.08	-138.28	-31.17
Capital & Investment Metrics	-	-	-
Invested Capital	13	-4.42	-51
Invested Capital Turnover	19.99	-3.25	-1.63
Increase / (Decrease) in Invested Capital	17	47	36
Enterprise Value (EV)	138	476	417
Market Capitalization	383	790	982
Book Value per Share	$5.24	$7.09	$11.92
Tangible Book Value per Share	$5.24	$7.09	$11.92
Total Capital	260	312	516
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-245	-314	-565
Capital Expenditures (CapEx)	2.44	9.96	31
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-60	-71	-79
Debt-free Net Working Capital (DFNWC)	175	205	286
Net Working Capital (NWC)	175	205	286
Net Nonoperating Expense (NNE)	64	76	96
Net Nonoperating Obligations (NNO)	-247	-316	-567
Total Depreciation and Amortization (D&A)	12	18	18
Debt-free, Cash-free Net Working Capital to Revenue	-71.86%	-78.19%	-70.17%
Debt-free Net Working Capital to Revenue	209.78%	226.83%	253.31%
Net Working Capital to Revenue	209.78%	226.83%	253.31%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($4.59)	($6.02)	($6.50)
Adjusted Weighted Average Basic Shares Outstanding	49.51M	43.73M	43.15M
Adjusted Diluted Earnings per Share	($4.59)	($6.02)	($6.50)
Adjusted Weighted Average Diluted Shares Outstanding	49.51M	43.73M	43.15M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.09M	44.43M	43.46M
Normalized Net Operating Profit after Tax (NOPAT)	-162	-188	-184
Normalized NOPAT Margin	-194.26%	-207.98%	-163.24%
Pre Tax Income Margin	-272.54%	-292.15%	-248.75%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-18.42	-39.07	-11.29
NOPAT to Interest Expense	-12.90	-27.35	-7.91
EBIT Less CapEx to Interest Expense	-18.61	-40.52	-12.61
NOPAT Less CapEx to Interest Expense	-13.10	-28.80	-9.23
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from REGENXBIO's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-4.50%	-16.31%	11.60%	-18.37%	-29.13%	9.06%	-38.81%	-13.86%	-91.75%	-13.85%
EBITDA Growth	19.30%	2.07%	22.05%	1.82%	-13.83%	8.56%	-16.63%	9.13%	-116.26%	-25.43%
EBIT Growth	19.92%	4.39%	23.35%	3.42%	-11.01%	8.62%	-17.13%	7.48%	-118.04%	-24.11%
NOPAT Growth	19.62%	4.44%	23.35%	3.47%	-10.61%	8.57%	-16.91%	7.51%	-113.48%	-23.88%
Net Income Growth	18.61%	3.67%	26.47%	5.02%	-4.93%	18.04%	-5.69%	13.10%	-120.38%	-29.24%
EPS Growth	30.28%	17.02%	36.75%	9.80%	-2.90%	19.43%	-5.06%	14.53%	-120.18%	-27.74%
Operating Cash Flow Growth	22.41%	17.93%	3.86%	31.47%	-3.53%	2.08%	23.36%	-44.73%	-111.53%	-18.71%
Free Cash Flow Firm Growth	41.84%	29.95%	-862.71%	44.05%	-19.44%	-42.81%	95.54%	-48.32%	-131.75%	-143.05%
Invested Capital Growth	388.77%	665.55%	260.70%	178.01%	91.35%	93.33%	-136.68%	86.50%	41.39%	24.79%
Revenue Q/Q Growth	-12.33%	8.53%	42.72%	-29.67%	-23.18%	44.74%	4.38%	-38.94%	18.23%	-18.80%
EBITDA Q/Q Growth	18.56%	-11.67%	11.50%	-0.27%	1.18%	11.12%	-11.48%	-16.26%	20.62%	-13.38%
EBIT Q/Q Growth	17.35%	-10.79%	12.25%	0.34%	1.33%	11.17%	-10.56%	-14.55%	18.77%	-13.86%
NOPAT Q/Q Growth	17.25%	-10.78%	12.25%	0.06%	1.63%	11.15%	-10.51%	-14.52%	18.68%	-13.61%
Net Income Q/Q Growth	14.11%	-12.47%	16.33%	-0.70%	-1.65%	14.15%	-8.08%	-11.25%	20.60%	-10.71%
EPS Q/Q Growth	15.38%	-11.43%	23.91%	2.82%	-0.71%	15.06%	-8.50%	-10.87%	21.14%	-10.76%
Operating Cash Flow Q/Q Growth	22.01%	10.88%	17.96%	-36.05%	17.50%	-4.41%	41.52%	-105.52%	21.97%	18.29%
Free Cash Flow Firm Q/Q Growth	21.81%	2.85%	-10.59%	30.77%	5.83%	-1,235.18%	93.57%	-47.81%	-12.59%	58.31%
Invested Capital Q/Q Growth	-38.73%	9.93%	133.04%	283.97%	-19.99%	68.76%	-13.12%	79.59%	7.57%	-271.88%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	93.79%	48.81%	52.55%	72.58%	49.41%	57.16%	52.57%	78.51%	59.22%	50.61%
EBITDA Margin	-228.05%	-245.52%	-238.62%	-384.80%	-269.89%	-209.81%	-341.66%	-319.92%	-168.02%	-250.25%
Operating Margin	-242.14%	-256.55%	-251.34%	-408.80%	-287.68%	-224.67%	-365.96%	-345.68%	-184.31%	-267.97%
EBIT Margin	-241.75%	-256.45%	-251.21%	-408.56%	-288.32%	-224.47%	-365.76%	-345.32%	-184.06%	-267.91%
Profit (Net Income) Margin	-241.28%	-246.30%	-237.67%	-405.39%	-283.12%	-213.97%	-360.72%	-348.40%	-191.21%	-284.72%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	99.76%	100.00%	100.00%	100.00%	99.93%	100.00%
Interest Burden Percent	99.81%	96.04%	94.61%	99.22%	98.43%	95.32%	98.62%	100.89%	103.96%	106.28%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-3,387.87%	-1,767.41%	-4,380.38%	0.00%	0.00%	0.00%	-2,442.39%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-3,382.46%	-1,762.42%	-4,376.70%	0.00%	0.00%	0.00%	-2,438.28%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	3,333.11%	1,716.97%	4,335.18%	0.00%	0.00%	0.00%	2,390.42%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-54.77%	-50.44%	-45.20%	-60.80%	-63.65%	-56.22%	-51.97%	-46.81%	-43.78%	14.36%
Cash Return on Invested Capital (CROIC)	-1,415.24%	-944.45%	-1,081.77%	-2,518.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-38.74%	-37.52%	-35.74%	-51.46%	-36.98%	-29.40%	-43.36%	-42.70%	-21.31%	-146.71%
Return on Assets (ROA)	-38.67%	-36.03%	-33.81%	-51.06%	-36.31%	-28.02%	-42.77%	-43.09%	-22.14%	-155.92%
Return on Common Equity (ROCE)	-54.77%	-50.44%	-45.20%	-60.80%	-63.65%	-56.22%	-51.97%	-46.81%	-43.78%	14.36%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-79.23%	-69.22%	-66.59%	0.00%	-71.75%	-67.55%	-58.11%	0.00%	13.06%
Net Operating Profit after Tax (NOPAT)	-36	-43	-39	-45	-45	-45	-51	-46	-40	-50
NOPAT Margin	-169.50%	-179.59%	-175.94%	-286.16%	-201.38%	-157.27%	-256.17%	-241.98%	-129.01%	-187.58%
Net Nonoperating Expense Percent (NNEP)	-5.41%	-4.99%	-3.69%	-4.34%	-4.11%	-3.33%	-4.11%	-3.28%	-2.75%	-4.46%
Return On Investment Capital (ROIC_SIMPLE)	-13.85%	-	-	-	-14.35%	-	-	-	-7.83%	-
Cost of Revenue to Revenue	6.21%	51.19%	47.45%	27.42%	50.59%	42.84%	47.43%	21.49%	40.78%	49.39%
SG&A Expenses to Revenue	94.52%	80.27%	84.57%	117.08%	85.89%	79.83%	118.63%	118.27%	67.67%	78.91%
R&D to Revenue	237.48%	224.94%	219.19%	351.07%	250.67%	201.23%	299.77%	305.76%	199.41%	238.81%
Operating Expenses to Revenue	335.93%	305.36%	303.89%	481.39%	337.09%	281.82%	418.53%	424.20%	243.53%	318.58%
Earnings before Interest and Taxes (EBIT)	-51	-62	-56	-64	-64	-65	-73	-66	-58	-71
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-48	-59	-53	-60	-60	-61	-68	-61	-53	-66
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.48	1.72	1.65	2.37	2.53	1.99	2.14	1.77	1.90	2.03
Price to Tangible Book Value (P/TBV)	1.48	1.72	1.65	2.37	2.53	1.99	2.14	1.77	1.90	2.03
Price to Revenue (P/Rev)	4.60	6.15	6.47	10.69	8.75	7.28	8.96	7.50	8.71	2.48
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.19
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.88%
Enterprise Value to Invested Capital (EV/IC)	10.83	11.52	13.15	67.24	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.66	2.84	2.80	6.30	5.27	3.61	4.68	3.18	3.70	1.14
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.99
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.57
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.72
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.03
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.14
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.99	-0.97	-0.99	-1.00	-1.07	-1.06	-0.98	-1.08	-1.11	-1.13
Leverage Ratio	1.82	1.73	1.66	1.61	1.70	1.64	1.58	1.54	1.52	1.64
Compound Leverage Factor	1.82	1.67	1.57	1.60	1.67	1.56	1.56	1.55	1.58	1.75
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.42	-0.69	-0.10	0.97	0.30	0.46	0.94	1.09	1.43	2.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.69	3.05	3.53	3.59	2.57	2.87	3.21	3.46	3.19	3.53
Quick Ratio	2.47	2.72	3.19	3.22	2.30	2.59	2.90	3.12	3.01	3.36
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-53	-68	-70	-63	-91	-97	-7.27	-113	-76	-68
Operating Cash Flow to CapEx	-2,930.86%	-12,438.34%	-9,598.52%	-9,956.01%	-3,619.89%	-3,433.43%	-1,836.32%	-1,679.49%	-719.78%	-999.13%
Free Cash Flow to Firm to Interest Expense	-5.64	-82.87	-155.78	-32.06	-67.02	-59.73	-6.49	-41.03	-17.74	-11.41
Operating Cash Flow to Interest Expense	-3.36	-49.45	-101.33	-28.11	-29.90	-30.42	-42.25	-29.37	-9.14	-8.47
Operating Cash Flow Less CapEx to Interest Expense	-3.47	-49.85	-102.39	-28.39	-30.73	-31.31	-44.55	-31.12	-10.40	-9.32
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.16	0.15	0.14	0.13	0.13	0.13	0.12	0.12	0.12	0.55
Accounts Receivable Turnover	3.68	3.27	4.03	5.00	3.41	3.28	3.29	4.78	3.73	11.74
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.67	0.66	0.68	0.64	0.66	0.72	0.70	0.79	0.83	3.51
Accounts Payable Turnover	1.25	1.86	2.75	1.37	1.49	1.65	2.76	1.79	2.83	2.76
Days Sales Outstanding (DSO)	99.13	111.77	90.57	73.00	106.93	111.28	110.81	76.37	97.98	31.09
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	291.21	196.22	132.77	266.73	245.21	221.63	132.37	203.97	129.15	132.09
Cash Conversion Cycle (CCC)	-192.08	-84.45	-42.21	-193.74	-138.28	-110.36	-21.56	-127.60	-31.17	-100.99
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	13	21	19	8.13	-4.42	-3.68	-12	-10	-51	-55
Invested Capital Turnover	19.99	9.84	24.90	-75.71	-3.25	-3.37	9.53	-2.50	-1.63	-7.17
Increase / (Decrease) in Invested Capital	17	24	31	19	47	52	-44	67	36	18
Enterprise Value (EV)	138	240	249	546	476	359	454	348	417	526
Market Capitalization	383	518	576	927	790	724	869	822	982	1,143
Book Value per Share	$5.24	$6.10	$7.07	$8.54	$7.09	$8.26	$9.34	$10.70	$11.92	$13.04
Tangible Book Value per Share	$5.24	$6.10	$7.07	$8.54	$7.09	$8.26	$9.34	$10.70	$11.92	$13.04
Total Capital	260	301	348	391	312	363	406	465	516	564
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-245	-279	-327	-381	-314	-365	-415	-474	-565	-617
Capital Expenditures (CapEx)	1.08	0.33	0.47	0.56	1.13	1.44	2.58	4.82	5.47	5.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-60	-45	-42	-53	-71	-63	-59	-55	-79	-69
Debt-free Net Working Capital (DFNWC)	175	211	248	285	205	238	261	277	286	313
Net Working Capital (NWC)	175	211	248	285	205	238	261	277	286	313
Net Nonoperating Expense (NNE)	15	16	14	19	18	16	21	20	19	26
Net Nonoperating Obligations (NNO)	-247	-281	-329	-383	-316	-367	-418	-476	-567	-619
Total Depreciation and Amortization (D&A)	2.91	2.65	2.81	3.71	4.09	4.24	4.82	4.86	5.03	4.68
Debt-free, Cash-free Net Working Capital to Revenue	-71.86%	-53.11%	-47.11%	-61.65%	-78.19%	-63.79%	-61.01%	-50.12%	-70.17%	-15.03%
Debt-free Net Working Capital to Revenue	209.78%	249.83%	278.97%	328.90%	226.83%	239.99%	269.06%	252.52%	253.31%	67.89%
Net Working Capital to Revenue	209.78%	249.83%	278.97%	328.90%	226.83%	239.99%	269.06%	252.52%	253.31%	67.89%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.99)	($1.17)	($1.05)	($1.38)	($1.42)	($1.41)	($1.66)	($1.53)	($1.38)	($1.75)
Adjusted Weighted Average Basic Shares Outstanding	49.51M	50.80M	50.60M	45.73M	43.73M	43.95M	43.53M	43.45M	43.15M	43.25M
Adjusted Diluted Earnings per Share	($0.99)	($1.17)	($1.05)	($1.38)	($1.42)	($1.41)	($1.66)	($1.53)	($1.38)	($1.75)
Adjusted Weighted Average Diluted Shares Outstanding	49.51M	50.80M	50.60M	45.73M	43.73M	43.95M	43.53M	43.45M	43.15M	43.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.09M	49.55M	49.42M	49.26M	44.43M	43.99M	43.96M	43.47M	43.46M	43.29M
Normalized Net Operating Profit after Tax (NOPAT)	-36	-43	-39	-43	-45	-45	-51	-46	-40	-50
Normalized NOPAT Margin	-169.50%	-179.59%	-175.94%	-276.75%	-201.38%	-157.27%	-256.17%	-241.98%	-129.01%	-187.58%
Pre Tax Income Margin	-241.28%	-246.30%	-237.67%	-405.39%	-283.80%	-213.97%	-360.72%	-348.40%	-191.35%	-284.72%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.45	-75.67	-124.74	-32.35	-46.99	-39.97	-65.24	-23.99	-13.39	-11.93
NOPAT to Interest Expense	-3.82	-52.99	-87.36	-22.66	-32.82	-28.00	-45.69	-16.81	-9.38	-8.35
EBIT Less CapEx to Interest Expense	-5.56	-76.07	-125.80	-32.63	-47.81	-40.85	-67.54	-25.74	-14.66	-12.78
NOPAT Less CapEx to Interest Expense	-3.93	-53.39	-88.42	-22.94	-33.65	-28.89	-47.99	-18.56	-10.65	-9.20
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About REGENXBIO's Financials

When does REGENXBIO's fiscal year end?

According to the most recent income statement we have on file, REGENXBIO's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has REGENXBIO's net income changed over the last 2 years?

REGENXBIO's net income appears to be on a downward trend, with a most recent value of -$227.10 million in 2024, falling from -$280.32 million in 2022. The previous period was -$263.49 million in 2023. See REGENXBIO's forecast for analyst expectations on what’s next for the company.

What is REGENXBIO's operating income?

REGENXBIO's total operating income in 2024 was -$233.35 million, based on the following breakdown:

Total Gross Profit: $54.76 million
Total Operating Expenses: $288.11 million

How has REGENXBIO revenue changed over the last 2 years?

Over the last 2 years, REGENXBIO's total revenue changed from $112.72 million in 2022 to $83.33 million in 2024, a change of -26.1%.

How much debt does REGENXBIO have?

REGENXBIO's total liabilities were at $206.34 million at the end of 2024, a 21.3% decrease from 2023, and a 34.9% decrease since 2022.

How much cash does REGENXBIO have?

In the past 2 years, REGENXBIO's cash and equivalents has ranged from $34.52 million in 2023 to $96.95 million in 2022, and is currently $57.53 million as of their latest financial filing in 2024.

How has REGENXBIO's book value per share changed over the last 2 years?

Over the last 2 years, REGENXBIO's book value per share changed from 11.92 in 2022 to 5.24 in 2024, a change of -56.0%.

Related Companies

This page (NASDAQ:RGNX) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Financials

Frequently Asked Questions About REGENXBIO's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Financials

Annual Income Statements for REGENXBIO

Quarterly Income Statements for REGENXBIO

Annual Cash Flow Statements for REGENXBIO

Quarterly Cash Flow Statements for REGENXBIO

Annual Balance Sheets for REGENXBIO

Quarterly Balance Sheets for REGENXBIO

Annual Metrics And Ratios for REGENXBIO

Quarterly Metrics And Ratios for REGENXBIO

Frequently Asked Questions About REGENXBIO's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools